J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.
Novartis reported early data showing its experimental actinium-based radiopharma drug demonstrated anti-tumor activity against prostate cancer, including in patients previously treated with its older therapies.
Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.
Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.
Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.
Research published in the Canadian Medical Association Journal found that survivors of cancer during their teen and young adult years face twice the risk of developing most types of subsequent cancers compared to the general population.
Scientists at St. Jude Children's Research Hospital, the American Society for Hematology, and Munich Leukemia Laboratory created a data-sharing platform that unites genomics, gene expression, and clinical data for blood cancers.
